Immune system ‘trainable’, door opens for cancer vaccine: study
| | |
December 26, 2007
Filed under Uncategorized
Mayo Clinic release – An international team of researchers led by Mayo Clinic have designed a technique that uses the body’s own cells and a virus to destroy cancer cells that spread from primary tumours to other parts of the body through the lymphatic system. In addition, their study shows that this technology could be the basis for a new cancer vaccine to prevent cancer recurrence.
The study appeared in the Dec. 9 online issue of Nature Medicine.
The technology combines infection-fighting T-cells with the vesicular stomatitis virus that targets and destroys cancer cells while leaving normal cells unharmed. The study, which has not yet been replicated in humans, is significant because it describes a potential new therapy to treat and prevent the spread of cancer in patients.
“We hope to translate these results into clinical trials. However, until those trials are done, it’s difficult to be certain that what we see in mouse models will clearly translate to humans. We’re hopeful that will be the case,” says Richard Vile, Ph.D., a Mayo Clinic specialist in molecular medicine and immunology and the study’s principal investigator.
In primary cancers of the breast, colon, prostate, head and neck and skin, the growth of secondary tumours often pose the most threat to patients, not the primary tumour. The prognosis for these patients often depends upon the degree of lymph node involvement and whether the cancer has spread.
Dr. Vile and colleagues theorized that they could control the spread of cancer through the lymphatic system (bone marrow, spleen, thymus and lymph nodes) by manipulating the immune system.
Researchers zeroed in on immature T-cells from bone marrow, programming them to respond to specific threats to the immune system while delivering a cancer-destroying virus to the tumour cells.
To deliver the virus, researchers removed T-cells from a healthy mouse, loaded them with the virus and injected the T-cells back into the mouse. Researchers found that once the T-cells returned to the lymph nodes and spleen, the virus detached itself from the T-cells, found the tumour cells, selectively replicated within them and extracted tumour cells from those areas.
The procedure used in this study triggered an immune response to cancer cells, which means that it could be used as a cancer vaccine to prevent recurrence.
“We show that if you kill tumour cells directly in the tumour itself, you can get a weak immunity against the tumour, but if you use this virus to kill tumour cells in the lymph nodes, you get a higher immunity against the tumour,” Dr. Vile says.
The technique used in this study successfully treated the cells of three different diseases: melanoma, lung cancer and colorectal cancer. The results include:
- Two days after treatment, the presence of melanoma tumour cells in lymph nodes was significantly less, but not completely gone. There were no cancer cells in the spleen.
- Ten-to-14 days after a T-cell transfer, both the lymph nodes and spleen were free of melanoma tumour cells.
- Mice treated with a single dose of the T-cells transfer developed a potent T-cell response against melanoma tumour cells.
- Although the procedure was not intended to treat the primary melanoma tumour, significant reductions in tumour cells were observed.
- In mice with lung cancer metastasis, cancer cells were significantly reduced in one-third of mice and completely eradicated in two-thirds of mice. Efforts to clear metastases from colorectal tumours were similarly effective.
- Lung and colorectal tumour cells were purged from lymph nodes. Also, the spleens of mice that had lung cancer developed immunity to the cancer after the treatment.
The technology already exists to extract T-cells from patients, attach the virus and inject the cells back into the patients. Doctors currently use a similar process to attach radioactive tracers to T-cells when trying to find the source of an infection in patients.
“This is technology that is relatively easy to translate to humans because it involves taking T-cells from the patient — something routinely done today — loading them with this virus and then putting those T-cells back into patients whose cancer has spread to lymph nodes, are at high risk of the cancer spreading to other parts of the body or are at high risk of succumbing to the cancer,” Dr. Vile says.
Other authors of the study include: Jian Qiao, M.D., Ph.D.; Timothy Kottke; Candice Willmon, Ph.D.; Feorillo Galivo; Phonphimon Wongthida; Rosa Maria Diaz, Ph.D.; Jill Thompson and Pamela Ryno of the Molecular Medicine Program at Mayo Clinic; Glen Barber of the Sylvester Comprehensive Cancer Center, University of Miami School of Medicine; John Chester, Peter Selby and Alan Melcher of the Cancer Research UK Clinical Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Molecular Medicine, University of Leeds, U.K.; and, Kevin Harrington, The Institute of Cancer Research, London.
This study was funded by the National Institutes of Health and Mayo Clinic.